✦ LIBER ✦

Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia

✍ Scribed by Andre C. Felicio; Clecio Godeiro-Junior; Patricia de Carvalho Aguiar; Vanderci Borges; Sonia M. A. Silva; Henrique B. Ferraz

Publisher: Springer Milan
Year: 2009
Tongue: English
Weight: 142 KB
Volume: 30
Category: Article
ISSN: 1590-1874
DOI: 10.1007/s10072-009-0097-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term botulinum toxin treatment incr

Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia

✍ Inger Marie Skogseid; Jo Røislien; Bjørgulf Claussen; Emilia Kerty 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB

## Abstract We examined the impact of cervical dystonia (CD) and long‐term botulinum toxin (BTX) treatment on employment status. Data on employment status at onset of CD, at initiation of BTX treatment, and at evaluation of long‐term treatment were obtained from 62 CD patients aged 31–66 years (med

Long-term follow-up of cervical dystonia

Long-term follow-up of cervical dystonia patients treated with botulinum toxin A

✍ Peter Haussermann; Stefanie Marczoch; Christiane Klinger; Michael Landgrebe; Bas 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 621 KB

## Abstract We followed the course in 100 consecutive patients with cervical dystonia (CD) after they were initially treated with botulinum toxin (BTX) in the form of Dysport 10 to 12 years ago. A total of 4 patients had died, and 6 were lost to follow‐up. Of the remaining 90 patients, 57 (63%) wer

Long-term treatment of cervical dystonia

Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency

✍ Kirn R. Kessler; Michael Skutta; R. Benecke; for the German Dystonia Study Group 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 167 KB

Long-term treatment with botulinum toxin

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

✍ Mitchell F. Brin; Cynthia L. Comella; Joseph Jankovic; Francis Lai; Markus Nauma 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

## Abstract To evaluate the immunogenicity of botulinum toxin type A (BoNTA; BOTOX) in cervical dystonia (CD). Subjects diagnosed with CD for ≥1 year and previously naïve to BoNTs were treated with BoNTA in a prospective, open‐label, multicenter study. Serum samples were analyzed for BoNTA neutrali

Long-term safety, efficacy, dosing, and

Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia

✍ Brian Berman; Lauren Seeberger; Rajeev Kumar 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

## Abstract Short‐term studies of cervical dystonia (CD) have demonstrated botulinum toxin type B (Bot B) to be safe and efficacious at doses of 5,000 to 10,000 units, but few long‐term studies have been published and the safety and efficacy of higher doses has not been established. Additionally, t

Autonomic cardiovascular function and ba

Autonomic cardiovascular function and baroreflex sensitivity in patients with cervical dystonia receiving treatment with botulinum toxin type A

✍ D. Tiple; S. Strano; C. Colosimo; G. Fabbrini; G. Calcagnini; M. Prencipe; A. Be 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 256 KB